Kinetic aspects of the interaction of blood clotting enzymes:VI. Localization of the site of blood-coagulation inhibition by the protein induced by Vitamin K Absence (PIVKA) by Hemker, H.C. & Muller, A.D.
  
 
Kinetic aspects of the interaction of blood clotting
enzymes
Citation for published version (APA):
Hemker, H. C., & Muller, A. D. (1968). Kinetic aspects of the interaction of blood clotting enzymes: VI.
Localization of the site of blood-coagulation inhibition by the protein induced by Vitamin K Absence
(PIVKA). Thrombosis et diathesis haemorrhagica, 20(1-2), 78-87.
Document status and date:
Published: 01/01/1968
Document Version:
Other version
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 03 Jun. 2020
Sonderdruck Reprint Tirage A, part
TDITOR,ES:  K .  M.  BRINKI IOUS,  CI IAPET,  HI ] ,L ;  T .  DEUTSC} I ,  WIEN;  R, .  GROSS,  KOIN;  J .  E .  JORPES,  STOCKHOLM;
F.  KO] ,T ,TR,3ASEL;  J .  ROSKANI ,  I IDGE;  SOL SHERRY,  PHI I ,ADELPEIA;  J . -P .  SOU] , IER, ,  PARIS;  I .  S .  WI i IGET,  NEW YORK
yol,. xx 15. XI. 1968 NO, U2
r;:. I Aj "v'
Kinetic Aspects of the Interaction of Blood-Clotting
Enzymes
VI. Localization of the Site of Bloorl-Coagulation Inhibition
by the Protein Inrlucetl by VitaminK Absence (PIVKA)
Irom the Laboratory lor Coagulotion Bi,ochemistry ond, CarrJi,oaascular Biochem'ical
Research' Depts ol Hae^*"|i:!,TJ.t;;i*'fl;i';ry;forolnternat' Med'icine' (Iniuersi'tE
U. C. ffr*r.un and A. D. Mur,r,nn
X"  K.  SCI IATTAUER,  VER,LAG .  STUTTGART-NEW YOR,K
In previous papers we have shown that the absence of functional vitamin K results
in the appearance in the circulation of an anticoagulant protein. This protein we
called PIVKA (Protein Induced by Vitamin K Absence or Antagonists) (8). This
result had been found with one reagent only, namely the Thrombotest reagent (13).
It thus seemed worth while to investigate if the inhibitor was specific for this reagent
or i"f it had to be considered a generally acting inhibitor of the blood coagulation
process. If so the site of action of this inhibitor had to be found out.
We concluded. from experiments reported in another article (4) that it is possible
to apply techniques derivecl from the disciplines of enzyme kinetics to the results of
clotting tests. The next step, obviously, is to use the kinetic approach to locate the site
at which PIVKA inhibits the coagulation reaction sequence.
Under the conditions prevailing in the test in which the inhibitor was first recognized
(i. e. the Thrombotest method), the concentration of factor X has been shorrn to be
rate-limiting for the velocity of the reaction (9). This suggests that inhibition takes
place at the site in the coagulation reaction sequence at which factor X is rate-limiting.
Since the inhibition appears to be of the competitive tgre, this finding further suggests
that PIVKA might be a substrate analogue of factor X. The evidence, howevet,
cannot be accepted as being more than suggestive. X'urthermore, there may be other
sites of inhibition that are not recognized by the Thrombotest method. It is therefore
evident that the effect of PIVKA must be localized more precisely.
It should be stressed once again that care must be taken not to conJuse the recti-
linear plots obtained by the graphical representation of clotting time as a function of
the inverse of the concentration of the rate-limiting clotting factor (i. e. tc - r/C plots)
with Lineweaver-Burk plots such as can be obtained" in the simpler and therefore
betterdefined systems used. in most errzyrne kinetic work.
Uncontrollable circumstances such as the concentration of clotting factors in the
plasma used as a reagent, make it impossible to draw conclusions about the actual
magnitude of the reaction constants of the system under study, or to draw any
conclusion whatsoever from comparison of experiments carried out with differont
reagent plasmas. Nevertheless, the construction of t" - 'lC plots is useful because
these plots show, at the intercept of the line obtained from the experiment and the
X-axis, the so-called minimal clotting time (tpi"). This minimal clotting time is the
clotting time that would be obtained, under the circumstances of the test, in the
presence of an infinite amount of the clotting factor, the inverse concentration of
Thrombos. Diathes. haemorrh. (Stuttg.)
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which is rendered on the X-axis. By application of this procedure, one variable of the
clotting reaction, i. e. the concentr'ation of one among the factors II, V, VII, or X,
can be eliminated. This enables us to draw conclusions as to the type and site of
inhibition, since the recognition of inhibition and the determlnation of the tyle of
inhibition does not require estimation of reaction constants.
Materials anil Methoils
Except for minor changos in the composition of the reaction mixturos as indicated in the next
section, materials and methods are the same as those indicated in proceeding articles (4, 8, 9). It
may be reminded that the reagent, plasmas in the specific tests whoro congonitally deffcient human
plasmas except for the factor V reagent, which was Ba-Stearato adsorbed normal human plasma
(10) and the second factor X reagent which was plasma from a patient with amyloidosis which
showed an acquired spocific factor X deficiency. Tho thromboplastin used was always human brain
thromboplastin prepared according to Owren and Aas (14).
Experimental
n'irst of all it was established that PIVKA does inhibit in a system fifferent from
Thrombotest. The results are shown in n'ig. 1. It is seen that in a reagent consisting
Ditution foctor'
Fig.l. The effect oJ PMA ,in a "prothrombi,n-ti.me" estimalion us'ing reagents oJ human ori,gin.
The reaction mixture consisted of 0,1 ml A1(OH)a adsorbod human plasma. 0.1mI human brain
thromboplastin; 0.1 ml samplo (if diluted, dituted. with Michaelis buffor); 0.1 ml CaCI, 26 mM.
The figures give tho means of 50 determinations. Whito squares: normal plasma; tho rogression
line through these points intercepts the Y-axis at t-ir : 12,3 sec f 0.2 sec (sd). Black squaross
mixed plasma from 6 patients on long torm anticoagulant troatment; the regression line through
theso points intercepts the Y-axis at tpil : 23,4 sec ;! 0.4 sec (sd). The signiffcant differonco
between t-i, of the normal plasma and t-io of tho abnormal plasma indicates tho action of PIVKA
(see ref, 8).
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of human brain tbromboplastin (prep. according to Owren & Aas) and adsorbed
human plasma the inhibitive action of PIVKA can be demonstrated, be it to a lesser
extend than with the Thrombotest method, and even to an extend which can be
barely observable when the experiments are not carried out in multiplo. In Fig. 1
however the prolongation of tmi'. obtained with Dicumarol plasma and vitamin K
deficient plasma is significant and so the fact that PIVKA can inhibit in a system
consisting entirely of material of human origin seems proven.
A first indication of the site of action of PIVKA is found in Table 1. In this ex-
periment, two plasmas with extremely low concentrations of factor II, VII, IX, and
X, and with a considerable amount of PIVKA present, were tested. The slope of the
t - D line obtained with Thrombotest and the amount of inhibitor could not be
assessed directly in these plasmas because of the extremely long coagulation times.
Consequently, the amount of inhibitor and the slope were estimated in a mixture of
equal parts of normal plasma and the unknown plasma. Because the slope and the
amount of inhibitor have been shown to be additive quantities in mixtures (8), the
values of the original plasmas could be calculated from the values obtained rmith the
mixtures.
Table 1. Coagulation Times in Specifically Deficient Systems in the Presence of Plasma from
Severely Vit. I( Deficient Patients.
Reagent Buffer
Pat. R
r l r  I  u10
Pat. B
l l r  I  r / 10
Factor II cong.
Factor II art.
Factor V art.
X'actor VII/X art.
Factor VIf cong.
Factor X acquired def.
Factor X cong.
4 0
89
195
l49
106
46
CU
42
46
I D
200
96
Y D
76
+D
oo
19
1 1 0
104
4 7
O J
37
38
1 6
158
84
40
co
1 q
t23
87
o f
1  D  K m .  It c ' h : u = r ( 1  *  E  ) *  n - . X
Patient R,: Attempted suicide by prolonged intake of Sintrom
Slopo t-D cl:rva: lo/o.Inhibitor: 1.8 U.
Patienf B: Bilo obstruction by carcinoma of the stomach
Slope t-D cr::rve:2o/o.Inhibitor: 2.0 U.
The figures give the means of 10 clotting time estimations expressed in sec.
It can be seen from Table I lhat as soon as factor X plays a rate limiting role in
the determination, a singular phenomenon occurs: the clotting time obtained with
the sample present is longer than the clotting time obtained with buffer substituted
for the sample. This finding suggests that PIVKA inhibits at the level of factor X.
These results again indicate that the inhibition is not limited to the Thrombotest
system, all reagents used in this experiment being of human origin.
It has been shown previously that a rectilinear plot is obtained when the clotting
time in a specific one-stage test is plotted against the inverse of the concentration of
the rate-limiting clotting facLor (4). This mode of plotting provides a means of locat-
ing the site of inlibition more precisely.
The clotting time in the presence of a competitive inhibitor can be represented by
the following formula (6)
K m * E
K i + E
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in which tc : clotting time; h - a constant; E : enzyne concentration; D : dilu-
tion factor; X : substrate factor concentration in the undiluted plasma; I : con-
centration of inhibitor in the undiluted plasma; Km and Ki : reaction constants.
According to this formula, the presence of an inhibitor results in a relatively less
important prolongation of the clotting time the greater the dilution of the sample
containing the inhibitor. This holds because an increase of the dilution factor (D)
causes an increase of the second terrn of the formula, but leaves the third term unchang-
ed sihce D does not figure in that term whereas it is the only term in which the con-
centration of the inhibitor figures. We can use this property to locate inhibition in the
following way:
From a normal standard plasma various filutions are made, and a ts - l/C plot is
constructed. as previously inficated. This plot gives the relation between clotting
time and clotting-factor concentration, and can therefore be used to read the clotting-
factor concentration belonging to a clotting time found with an unknown sample.
When the same sample is tested in various dilutions, multiplication of the con-
centration read on the standard curve by the dilution factor gives the concentration
of the original sample. When no inhibitor is present, the concentration thus calculated
to be present in the original sample will be the same, independent of the dilution from
which the calculation has been made.
We have shown above that when an inhibitor is present, the inhibition becomes
less important the more the plasrna sample containing the inhibitor is diluted. There-
fore, with a sample containing a competitive inhibitor more realistic, i. e. higher values,
will be found when the estimation is done by testing the sample in a high filution
than when the sample is tested, in relatively concentrated form.
The best approximation will be found with the sample in its highest dilution. Of
course, the practical aspects of the estimation of clotting times set a limit to the dilu-
tion that can be used.
The procedure is illustrated in Tables 2 and 3, from which it is evident that Di-
cumarol plasma shows essentially the same amount of factor II no matter from rrhat
dilution of the sample this amount has been calculated. Factor X, however, shows a
level that appears to be lorn' when calculated from a low dilution and when calculated
from a high dilution appears to be high. This indicates that an inhibitor of the rate-
limiting reaction in a factor X estimation is present in the unknown sample.
Clotting time
tsec.)Dilution
Concent'ration
in samplo (o/o)
Concentration
in plasma (o/o)
l : 4
l : o
1 : 8
1 :  1 0
I z 1 2
L :  1 4
1 :  1 6
27.4
29.r
32.O
29.8
25.0
29.7
28.8
The clotting times have been obtained in a specific one stago estimation of factor II using
congenitally factor II deficient plasma as a substrate, The third column gives tho concent'rat'ion
present in the (diluted) sample according to a reference curve obtained with normal plasma. The
fourth column gives the concentration in the undiluted Marcoumar plasma as calculated from
columns 1 and 3.
Table 2. Estimation of the Factor II Content in Marcoumar Plasma.
32.9
38.3
4 1 . 8
o J . o
5  t . b
o r . o
o . 6 D
4.85
4.00
2.98
o  A q
2 . 1 2
1.80
Tablo 3. Estimation of tho Factor X Contont in Marcoumar Plasma.
80.7
69.7
72.L
73.6
71.3
74.4
79.6
82
Dilution
Concentration
in plasma (o/o)
l t 4
1 : 6
1 : 8
1 :  1 0
1  . 1 '
l : 1 4
1 :  1 6
1 . 8 7
2.50
2.33
o q q
2.38
2 . 1 5
1.92
l . D
15.0
18.6
q o o
28.5
30.1
30.6
The clotting times havo been obtained in a specific one stage estimation of factor X using
congenitally factor X deficient plasma as a substrate. The third column gives the concentration
prosent in the (diluted) sample according to a reference curve obtained with normal plasma. The
fourth colurnn gives the concontration in the undiluted Marcoumar plasma as calculatod from
colurrrrs 1 and 3,
As already indicated, the level found with the sample in its highest dilution is the
best approximation of tho real amount present. By using this approximation, we can
design experiments showing inhibition in clotting tests in a set-up analogous to the
classical Lineweavor-Burk plot. fn these experiments a fixed amount of Dicumarol
plasma is mixed with an equal amount of various dilutions of normal plasma. Con-
sequently, in these mixtures a fixed amount of PI\IKA is present along with Yariable
a,mounts of the clotting factors. When these mixtures are subjected to a specific test,
tho amount of the ratelimiting clotting factor present in that test is known because
:we know the (variable) amount present in the diluted normal plasma as well as the
amount present in the reagent (4), and we have a reasonable approximation of the
Fig.2.  Fig.3.
Fig.2. The effect of PIVRA'in a Jactor II estti,mati,on. The clotting timo obtained in a,n one stago
factor II estimation is plotted against tho inverso of tho factor II concentration present; in absence
(open dots) or in presence (black dots) of a ffxed amount, of PIVKA. No differenco is observed.
Big,3. TheeffeotoJ PIVKAimaJactor X esti,mati,om, Tho clotting time obtained inaone stage
factor X estimation is plotted against the inverse of tho factor X concontration. Congenitally
factor X deficient plasma was used as a roagent in the factor X estimation, A pronoulced inhibition
is evident in prosenco of PIVITA (upper curve). At inffrtite factor X concontration, i. e. a0 the
intorcopt with tho Y-axis PrVI{A has no effoct. This indicates a compotitivo type of inhibition.
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amount present in the Dicumarol plasma. Comparing the
presence and in the absence of PI\IKA, .we see again that
obvious in factor X estimations but is not maniJested in
(Figs.2, 3 and 4).
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1lFoc+orXl%l X'ig.4. 1lFoctorY (%J
Fig.4. The effect oJ P IVKA i'm afactor X est'imation. AsinX'ig.3 except thatplasma with an acquired
factor X deficiency due to amyloidosis has beon used as a reagent,
Eig.5. The effect oJ PMA i'n a factor V eatdmatdom. The clotting time obtained in a ono stage
factor V estimation is plotted against the inverso of the factor V concentration in absence (lower
curve) and in presence (upper curve) of a fixed amount of PIVKA. A slight irrhibition is observed.
F ig .7 .
l/FoctorVll (%) X'ig. 0. Ditution foctor
Fig.6. llhe effect oJ PIVRA 'im a Jactor VII estimation The clottipg time obtained in a ono stage
factor YfI estimation is plotted against the inverse of the factor VII concentration in absence
(Iowor curve) and in presence (upper curve) of a fixed amount of PIVKA. A slight irrhibition is
oDserveo.
Fig.I. llhe effect oJ PIVI<A i,n the i,ntri,nsi,c coagulatiom system. Pneae|ion mixture: 0.2 ml plasma
diluted with Bason adsorbed plasma; 0.1 ml suspension of Kaolin (5 mg/ml) and phospholipid;
0.1mI CaClr; 25mM. The plasma used was eithor normal plasma (lower curvo) or Marcoumar
plasma (upper curvo). In this type of graph, whero the inhibitor is diluted along with the substrate,
the fact that ihe Marcoumar plasma gives a straight line that does not extrapolate to tho same
point at the Y-axis as the line obtained with normal plasma does again indicate the presenco of
a competitive inhibitor (ref. 6, 8).
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The results obtained. with factor V and factor VII estimations are shown in X'igs.5
and 6 respectively. Both show a certain amount of inhibition, although much-less
than the inhibition in a factor X estimation. X'is.7 shows that the inhibitor is also
active in a sysfem in which the intrinsic rather than the extrinsic clotting system is
operative.
Discussion
In the first place it must be remarked that the inhibition by PIVKA is not, a unique
feature of the Thrombotest reagent. It is also observed when using reagents of human
origin both in the extrinsic and the intrinsic system (X'igs.1 and T).
The discussion of the experiments designed io locate the site of the action of PIVKA
is necessarily based on our present concept of the uninhibited reactions involved in
thrombin formation. On the basis of recent studies (1,3, 4, 5,7), a fairly detailed
reaction scheme can be written:
xlra
XIIa + X A. C. P.
(A)
(B)
(c)
(D)
A. C.  P.
* Ca++
VII"
a
X " * V * P h . l i p . n Q a prothrombinase
prothrombinase
Thrombin
(T. F. : tissue factor; Ph. lip. : phospholipid: A. C. P. : activated contact product)
n'actor VIII probably must be acted upon by thrombin before it can react in
reaction D (15). Tactor V possibly must be activated by thrombin or in some other
way before it can take part in reaction f' (12). The reasons why this scheme has to be
preferred to the original cascad.e scheme (2, It) have been discussed elsewhere (4, 5, 7 ).
The location of the site at which PIVKA is inhibitory will be discussed in terms of
this reaction scheme.
n'ig.2 shows that when factor II is rate-limiting, PIVKA does not influence the
reaction rate. This excludes reaction H as a possible site of action of PIVKA.
A strong competitive inhibition is observed when factor X is present in rate-
limiting amounts (n'ig.3). This indicates that PIVKA inhibits a reaction in which
factor X is involved (i. e. either reaction T or reaction G). The facb lhat the inhibition
is of a purely competitive type suggests that PIVKA is a substrate analogue of
factor X. To exclude the possibfity that the inhibition was due to a specific property
of the congenitally deficient plasma used as a reagent, another reagent was also
tested., which gave essentially the same results (n'ig.a).
n'rom X'igs.5 and 6 it can be seen that a certain amount of inhibition can be ob-
served in both the factor V and factor VII test. A possible explanation of this pheno-
menon might bo found in the assumption of the existence of factor V and factor WI
analogues in Dicumarol plasma.
I X " * V I I I + P h . l i p .
A. C. P. or T. F.
X-ase or-Vfls,
IX
vtr (E)
(F)
(G)
(H)
X
X-ase
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In view of the fact that factor V is known to be unaffected by the presence or absence
of vitamin K, this possibility must be regarded as unlikely in th'e case of factor V,
especially since an alternativ_e explanation is available tlat does not require the
postulation of more than one abnormal protein.
The inhibition of factor VII converiion is apparently not very extensive and is
not of a_clearly competitive type. If a factor VII analogue were present as well as a
f.u:lo" 4 analogue, one would ixpect an easily recogniZable codpetitive inhibition.Although the possibility that a -tqntty inhibitory "factor VII a'nalogue is present
cannot be ruled out, the experiments do not seem to justify postulation o-f its existence,
since the observed inhibition can also be explained on the-basis of the existence of a
factor X analogue onlv.
rf we assumi that ;hefrvKA present in the plasma in vitamin K d.efi.ciency is an
analogue of factor X and that it can be converted into an analosue of activated fac-
tor X (called PIVKA* heneeforward) by the enzyme for which fa"ctor X is the normal
substrate, i' e. by either activated factor VII or ten-ase, we have explained" the fact
that PrvKA is not observed in the serum obtained from Dicumaroi plasma (s). At
the same time, we also have an explanation for the inhibition observedin a factor VItr
test. Since factor VfI is tested in the presence of an excess of its normal substrate(factor X), we would not expect the amount of prvKA introduced. with the sample
to give rise to a marked inhibition. If the product of the action of factor VII on PIVKA
is adsorbed onto phospholipid in the same rray as its analogue factor Xr, this would.
furnish an explanation for the inlibition obseived in factori tests. Tho i'activated',
PIVKA would react with phospholipid and factor V to form an inactive prothrombi-
nase according to the reaction formula:
PIVKA* * Ca++ + V + ph. lip g inactive prothrombinase (I)
I_n this complex a certain amount of the rate-Iimiting factor V would. be taken up,
and therefore a certain amount of inhibition would be afparent. Again, this inhibitiJn
cannot tre expected to be very extensive, since an 
"*c"ss 
bf normaffactor X is present
under these circumstances.
X'ig.7 shows that inhibition can be demonstrated to occur in the intrinsic coasula-
tion system, i. e. in a system in which factor Vrr does not play a rate-determlning
role but factor X does.
__c_ons.equently, all the o_bserved phenomena can be explained. by one.hypothesis:PrvKA, a substrate analogue of factor X, can be conier-ted inio an anilogue of
factor Xr by either factor VII or ten-ase. In its converted. form it can take the-place
of normal factor Xa in prothrombinase, which makes this prothrombinase ina&ive.
The fact that inhibition is observed in the intrinsic system l-eaves open the possibility
that an inhibitor of factor fX conversion is also present in the bldod of vitamin K-
deficient or Marcoumar treated patients. Because the Thrombotest reaction is essen-
tially insensitive to any variation of the concentrations of factor IX, such an inhibitor
could not be the same as the one_recognized as PIVKA. Whether or not an inhibiting
substrate analogue of factor fX exists will have to be determined bv further inl
vestigations.
The fact that the inhibitory action of prvKA is more pronounced with one phos-
pholipid (that in Thrombotest) than with an other humian brain ThromboplJst in
might be explained by one of the following hypotheses:
a) rn the reaction mixture prepared from human material factor X is not as
strictlyrate-limiting as it is in the Thrombotest system; consequently introd.uction of a
specific factor-X-inhibitor (i. e. PIVKA) would h-ave less influeirce ott thu reaction rate.
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b) The competition for factor Xr binding sites between factor X6 and PI\4KA given
by the following reactions:
K
V * Xa * Ca++ f Ph. lip + prothrombinase
R,
V + PIVKA * Ca++ 1 Ph. Iip = inactive prothrombinase (I)
at given concentrations of the reactants is determined by the ratio of the values K
and R,. This ratio thus determines the efficaciousness of the inhibition. As phospho-
lipid is a reactant in both reactions it can be considered lii<ely that this ratio is
dependent upon'the kind of phospholipid used.
In conclusion, it may be said that the experiments reported here provide &n ex-
planation of the inhibition first found in the Thrombotest reaction, in terms of the
postulation of the existence of an analogue of factor X in vitamin K deficiency. The
postulation of analogues of the other vitamin K-dependent clotting factors proved
to be unnecessary, although the existence of such analogues could not be ruled out.
The degree of inhibition is influenced by the kind of phospholipid present in the test.
The inhibition is not however specific for one special kind of thromboplastin.
Summary
PIYKA, the circulating anticoagulant protein found in vitamin K deficiency can,
on kinetical grounds, be recognized as an analogue. of factor X. The existence o{
analogues of other vitamin K-dependent clotting factors cannot be ruled out, but
need not be assumed to explain the experimental results.
R6sum6
PIVKA, la prot6ine anticoagulante circulante dans les cas de d6ficience en vita-
mine K peut 6tre reconnue sur des bases cin6tiques comme un analogue du facteur X.
L'existence d'analogues des autres facteurs de la coagulation d6pendant de la vita-
mine K ne peut 6tre exclue, mais n'est pas utile pour expliquer les r6sultats exp6ri-
mentaux.
Zusarnmenf assung
' Das beim Vitamin-K-Mangel gefund.ene zirkulierende antikoagulierende EiweiB,
PIVKA, wurde auf Grund kinetischer lJntersuchungen als ein Protein identifiziert,
das dem Faktor X analog ist. Die Existenz von analogen EiweiSen anderer Vitamin-
K-abhd,ngiger n'aktoren kann nicht ausgeschlossen werden. Sie ist jedoch nicht not-
wendig, um die experimentellen Resultate zu erkld,ren.
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Ail,ilend,um
Experiments in which plasma congenitally deficient i4 factorV was usod, confirmed the rosults
obtained rarifh the artificially doffcient factor V reagent doscribod in this articlo.
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